A5072652305- Intraperitoneal and Appendiceal Malignancies
- Hormonal Regulation and Hypertension
- Prostate Cancer Treatment and Research
- Nanoparticle-Based Drug Delivery
- Nanoplatforms for cancer theranostics
- Adrenal and Paraganglionic Tumors
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Archaeological and Geological Studies
- Archaeological and Historical Studies
- Cell Adhesion Molecules Research
- Electron and X-Ray Spectroscopy Techniques
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Acute Myeloid Leukemia Research
- Cancer Cells and Metastasis
- Congenital heart defects research
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Biosimilars and Bioanalytical Methods
- Ubiquitin and proteasome pathways
- Animal testing and alternatives
University of California, San Francisco
2022-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2022-2024
Vall d'Hebron Institut de Recerca
2020-2023
Universitat Autònoma de Barcelona
2020-2023
Universidad de Granada
2021
Spanish National Cancer Research Centre
2014-2017
Abstract Targeted degradation of cell surface and extracellular proteins via lysosomal delivery is an important means to modulate biology. However, these approaches have limitations due lack modularity, ease development, restricted tissue targeting applicability both proteins. We describe a strategy, termed cytokine receptor-targeting chimeras (KineTACs), that addresses limitations. KineTACs are fully genetically encoded bispecific antibodies consisting arm, which binds its cognate receptor,...
Significance Noonan syndrome (NS) is a developmental disorder caused by germ-line mutations in various components of the RAS signaling pathway. The pathophysiological mechanisms underlying clinical manifestations NS patients and basis for observed phenotypic variability are poorly understood. To date, mouse models carrying Protein Tyrosine Phosphatase Non-Receptor type 11 ( Ptpn11 ), Son Sevenless homolog 1 Sos1 Raf1 loci have been described. new model described here, induced K- Ras V14I...
The tumor uptake of large non-targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved 4-arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate-specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA-targeted delivery therapeutic efficacy, StarPEG nanodrugs with/without three copies PSMA-targeting ligands, ACUPA, are...
Abstract Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express protein conformations are invisible to standard target discovery pipelines evaluating gene or expression, and these can be identified immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein capture ‘structural surfaceomics’. As proof...
Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains mainstay treatment but disease recurrence death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients.
Background A critical challenge in the management of Glioblastoma Multiforme (GBM) tumors is accurate diagnosis and assessment tumor progression a noninvasive manner. We have identified Membrane-type 1 matrix metalloproteinase (MT1-MMP) as an attractive biomarker for GBM imaging since this protein actively involved growth progression, correlates with grade closely associated poor prognosis patients. Here, we report development immunoPET tracer effective detection MT1-MMP models. Methods An...
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are urgent need additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target other cancers, specifically upregulated cell surface antigen high risk myeloma tumors. We use structure-guided design to define CD27-based anti-CD70 CAR-T that outperforms all tested scFv-based CARs, leading >80-fold improved...
<p>Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) tumors over left flanks.</p>
<p>Supplementary Figure S11. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S4. Coronal μPET/CT fusion and MIP images obtained at 18 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing 22rv1 subcutaneous tumors over left flanks.</p>
<p>Supplementary Figure S22. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day 89Zr labeled nanocarrier injection.</p>
<p>Supplementary Figure S8. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing 22rv1 subcutaneous tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S17. Immunofluorescence CD31 staining of the respective tumor tissue sections using rat anti-mouse antibody indicating vascular development in different phenotypes.</p>
<p>Supplementary Figure S18. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day [89Zr]PEG-DFB1-TLZ3 injection. Black arrows indicate presence tumors.</p>
<p>Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>